GlassScriptPhysician profile
Eric C Tangalos
NPI 1528045952
$141,373.96
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $29K · 2021: $13K · 2022: $40K · 2023: $13K · 2024: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Travel and Lodging: $2,632 · Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,993.86 |
| Travel and Lodging | $2,631.62 |
| Food and Beverage | $981.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45,080.78 | 2020-2024 | |
| Eli Lilly and Company | $26,481.25 | 2019-2020 | |
| Biogen, INC. | $20,791.55 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $11,511.89 | 2022-2024 | Nuplazid |
| Genentech, INC. | $11,201.25 | 2021-2022 | |
| Genentech USA, INC. | $9,752.13 | 2019-2022 | |
| Axsome Therapeutics, INC. | $7,915.11 | 2024 | |
| Roche Products Limited | $6,240.00 | 2020-2022 | |
| F. Hoffmann-La Roche Ag | $2,400.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tangalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.